

Genomtec S.A. signs an agreement with Clairfield Partners LLC to advise on sale of company to industry investor

Genomtec S.A., a medical technology company specializing in the development of advanced technologies in the field of genetic diagnostics, has signed an agreement with Clairfield Partners LLC, the New York based member firm of Clairfield International (“Clairfield”). The purpose of the agreement is to advise on the process of establishing strategic partnerships, selling licenses and/or selling all or part of Genomtec’s intellectual property and related technology. Clairfield has extensive experience in M&A transactions in the areas of medical technology including molecular diagnostics.

Clairfield will be responsible for identifying and selecting potential buyers and partners. These activities will include, among other things, drafting the necessary materials and establishing contacts with global healthcare companies. In addition, Clairfield will support Genomtec in organizing the due diligence process, shaping the negotiation strategy and coordinating the process of final discussions related to the transaction.

- We consider the commencement of cooperation with such an experienced partner as Clairfield as a validation of the attractiveness of Genomtec technology. It is a result of many years of work by our team that has allowed Genomtec to be at the current stage of development. We already have an operational Genomtec ID platform with a diagnostic panel certified in 30 European countries. We own 9 patents in Europe, the U.S. and Japan and have more than 25 patent applications in global markets. Our current priority is to select a global strategic partner determined to purchase a license, or acquire all or part of Genomtec's technology - said Miron Tokarski, Chief Executive Officer and co-founder of Genomtec S.A.

Clairfield's services will be provided on an exclusive basis. The remuneration for the services includes a variable part, the so-called success fee, dependent on the result, and a fixed part, spread over several payments. The terms of the agreement do not differ from those commonly seen in these types of contracts.

- We are pleased to be working with Genomtec and look forward to assisting them as they realize their full potential in the molecular diagnostic market - said Crosby O’Hare, Managing Partner of Clairfield International.

Clairfield Partners LLC is part of Clairfield International SA - a multinational company providing corporate finance services, mainly in the area of mergers and acquisitions, to multinational corporations and financial investors. Clairfield has extensive experience in conducting mergers and acquisitions in the medical sector. www.clairfield.com

Clairfield International healthcare: <https://www.clairfield.com/sectors/healthcare/>

About Genomtec:

Genomtec is a innovative medical technology company specializing in developing advanced technologies in the area of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows fast and precise molecular analysis outside the laboratory environment without the need for skilled laboratory personnel. The solution uses microfluidic technology and proprietary, patent-protected SNAAT isothermal technology. The company's technology is protected by 9 patents in Europe, the U.S. and Japan and more than 25 patent applications in global markets.

The company has CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory infections caused by such pathogens as: SARS-COV-2, RSV, Influenza A and B, and two bacterial pathogens.

The company is headquartered in Wroclaw, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information is available at: www.genomtec.com

Contact for media:

Kamil Majcher

NewTech Comm

k.majcher@newtechcomm.pl

+48 507 649 596